Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -8.86%17 Earnings per Share (Diluted) is $-0.04 as of Mar. 2026. GuruFocus rates HKPD with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 99 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 1010100% on this metric.
Cellyan Biotechnology Co (NAS:HKPD) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Cellyan Biotechnology Co Earnings per Share (Diluted) Related Terms
Cellyan Biotechnology Co Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Cellyan Biotechnology Co's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co Earnings per Share (Diluted) Chart
HKPD vs COSM, YI, MEDS: Earnings per Share (Diluted) Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's PE Ratio falls into.
Cellyan Biotechnology Co Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Cellyan Biotechnology Co's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.04 mean?
Cellyan Biotechnology Co (HKPD) has a Earnings per Share (Diluted) of $-0.04 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Cellyan Biotechnology Co and its competitors. According to the industry distribution chart, Cellyan Biotechnology Co ranks #999999 out of 99 companies in the Medical Distribution industry.
Is Cellyan Biotechnology Co's Earnings per Share (Diluted) too high?
Cellyan Biotechnology Co's current Earnings per Share (Diluted) is $-0.04. Based on the distribution chart, Cellyan Biotechnology Co ranks #999999 out of 99 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Earnings per Share (Diluted) compare to COSM and YI?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #999999 out of 99 companies for Earnings per Share (Diluted). This places Cellyan Biotechnology Co in the lower half of its industry. The industry median Earnings per Share (Diluted) is 4.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Distribution company?
The median Earnings per Share (Diluted) among Medical Distribution companies is 4.70, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Earnings per Share (Diluted) is 4.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Earnings per Share (Diluted) is $-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Earnings per Share (Diluted) of $-0.04. The current Earnings per Share (Diluted) is $-0.04. Cellyan Biotechnology Co's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Earnings per Share (Diluted) is $-0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
17GF Score
Get the complete analysis for HKPD
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
